Market open
Alto Neuroscience/$ANRO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Ticker
$ANRO
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
88
Website
ANRO Metrics
BasicAdvanced
$84M
-
-$3.05
-
-
Price and volume
Market cap
$84M
52-week high
$18.35
52-week low
$3.00
Average daily volume
235K
Financial strength
Current ratio
13.095
Quick ratio
12.965
Long term debt to equity
6.812
Total debt to equity
9.384
Interest coverage (TTM)
-45.33%
Management effectiveness
Return on assets (TTM)
-32.36%
Return on equity (TTM)
-56.72%
Valuation
Price to book
0.51
Price to tangible book (TTM)
0.51
Price to free cash flow (TTM)
-1.229
Growth
Earnings per share change (TTM)
-65.52%
What the Analysts think about ANRO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
ANRO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ANRO News
AllArticlesVideos
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Accesswire·1 day ago
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
Business Wire·2 days ago
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation
Accesswire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Alto Neuroscience stock?
Alto Neuroscience (ANRO) has a market cap of $84M as of February 21, 2025.
What is the P/E ratio for Alto Neuroscience stock?
The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of February 21, 2025.
Does Alto Neuroscience stock pay dividends?
No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of February 21, 2025.
When is the next Alto Neuroscience dividend payment date?
Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alto Neuroscience?
Alto Neuroscience (ANRO) does not currently have a Beta indicator.